Frequently Asked Questions
The most-asked questions about autoinflammatory syndromes.
What exactly are autoinflammatory syndromes?
They are a family of rare disorders in which the innate immune system launches inflammatory attacks with no external trigger such as infection or autoantibody. The result is a cycle of fever, rash, joint pain, and organ inflammation that the body cannot switch off on its own.
How do they differ from autoimmune diseases?
Autoimmune conditions recruit the adaptive immune system (antibodies, T-cells) to attack self-tissue, whereas autoinflammatory syndromes stem from the innate system overproducing cytokines like IL-1. A patient with FMF or CAPS will test negative for autoantibodies yet still have CRP through the roof during a flare.
What are the most well-known types?
The three that come up most often are Familial Mediterranean Fever (FMF), Cryopyrin-Associated Periodic Syndromes (CAPS), and TNF-Receptor-Associated Periodic Syndromes (TRAPS). Mevalonate kinase deficiency (HIDS), DADA2, and Behçet's disease round out the core group most patients and clinicians discuss.
Who are the key figures in the field?
French geneticists who cloned the MEFV gene in 1997 and the teams that subsequently linked NLRP3 mutations to CAPS and TNFRSF1A mutations to TRAPS are the names most often cited. On the treatment side, the researchers who ran the pivotal IL-1 blockade trials (anakinra, canakinumab) turned a previously untreatable group of diseases into manageable ones.
Where should a newcomer start learning?
Anchor yourself in the inflammasome pathway and the IL-1 axis first, because that single molecular thread ties together most of the conditions. Once that clicks, the individual syndromes (FMF, CAPS, TRAPS, HIDS) become variations on the same theme rather than a list of unrelated diseases.
What do the symptoms typically look like?
Patients usually report recurrent episodes of high fever (often 39–40 °C) lasting one to six days, paired with serositis, evanescent rashes, arthralgia, and—depending on the subtype—uveitis or vasculitis. Between flares many feel entirely well, which is a major reason the condition gets misdiagnosed for years.
How do doctors actually diagnose them?
The workup leans on a detailed personal and family history plus targeted genetic testing for the relevant gene (MEFV, NLRP3, TNFRSF1A, MVK, and others). Inflammatory markers spike during a flare and normalize between episodes, a pattern that helps separate these from chronic autoimmune disease.
What treatments actually work?
Colchicine has been the backbone of FMF management since the 1960s and remains first-line. For IL-1–driven conditions like CAPS and HIDS, biologic agents that block IL-1 (anakinra, canakinumab, rilonacept) have been transformative, often eliminating flares altogether, while newer IL-18 and IL-36 inhibitors are entering trials for rarer subtypes.
What was the landmark discovery that changed the field?
The 1997 identification of the MEFV gene proved that a single missense mutation in an inflammasome component could drive an entire clinical syndrome. That finding shifted the field from descriptive, symptom-chasing medicine to molecular genetics and opened the door to mechanism-based targeted therapy.
Are they inherited, and how common are they?
Most follow a clear Mendelian pattern—autosomal dominant for TRAPS and CAPS, autosomal recessive for FMF and HIDS—so they cluster in families but can also appear as de novo mutations. Each individual syndrome is rare (FMF hits roughly 1 in 250 in Mediterranean populations but is far less common elsewhere), and the whole group collectively affects an estimated 1 in 10,000 to 1 in 25,000 people worldwide.